- In its most recent trading session, VSCI has closed at a price level that was not very different from its closing price of one year earlier. This is probably due to its weak earnings growth as well as other mixed factors. Turning our attention to the future direction of the stock, we do not believe this stock offers ample reward opportunity to compensate for the risks, despite the fact that it rose over the past year.
- 35.05% is the gross profit margin for VISION-SCIENCES INC which we consider to be strong. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -52.69% is in-line with the industry average.
- Net operating cash flow has increased to -$0.95 million or 33.40% when compared to the same quarter last year. In addition, VISION-SCIENCES INC has also vastly surpassed the industry average cash flow growth rate of -22.24%.
- VISION-SCIENCES INC has improved earnings per share by 20.0% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. During the past fiscal year, VISION-SCIENCES INC continued to lose money by earning -$0.16 versus -$0.22 in the prior year.
- The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Health Care Equipment & Supplies industry average. The net income increased by 18.8% when compared to the same quarter one year prior, going from -$2.43 million to -$1.98 million.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. The Health Care sector as a whole closed the day up 0.2% versus the S&P 500, which was unchanged. Laggards within the Health Care sector included Aoxing Pharmaceutical ( AXN), down 4.8%, XTL Biopharmaceuticals ( XTLB), down 6.3%, ImmuCell ( ICCC), down 2.5%, Vision-Sciences ( VSCI), down 3.0% and VBI Vaccines ( VBIV), down 2.8%. TheStreet Ratings Group would like to highlight 3 stocks that pushed the sector lower today: Vision-Sciences ( VSCI) is one of the companies that pushed the Health Care sector lower today. Vision-Sciences was down $0.03 (3.0%) to $0.96 on heavy volume. Throughout the day, 60,833 shares of Vision-Sciences exchanged hands as compared to its average daily volume of 23,000 shares. The stock ranged in price between $0.94-$1.05 after having opened the day at $1.05 as compared to the previous trading day's close of $0.99. Vision-Sciences, Inc., through its subsidiaries, designs, develops, manufactures, and markets endoscopy products. It operates through Medical and Industrial segments. Vision-Sciences has a market cap of $48.0 million and is part of the health services industry. Shares are up 1.0% year-to-date as of the close of trading on Tuesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings rates Vision-Sciences as a sell. The area that we feel has been the company's primary weakness has been its relatively poor performance when compared with the S&P 500 during the past year. Highlights from TheStreet Ratings analysis on VSCI go as follows: